was a publicly traded canadian pharmaceutical company based in montreal quebec it was acquired by prometic life sciences in 2016 ceo michael berendt prior to joining telesta was the president and ceo of aegera therapeutics telesta was listed on the toronto stock exchange under the symbol tst as part of the strategic push to focus on late stage human therapeutics effective may 2014 the company divested its animal health unit to v toquinol a family owned global animal health company led by ceo matthieu frechin in 2014 a court decision involving a group of bioniche shareholders and the bioniche board of directors established a precedent in the canadian court system for conditions under which a board may choose not to select the date proposed by shareholders for an annual meeting but rather schedule on a date of the board s choosing thus confirming that directors have wide latitude to manage corporate affairs in february 2016 the biologics license application of telestra s main drug mcna was rejected by the fda in response the company started cutting staff and attempted to find a buyer for its belleville and montreal production facilities in august telesta was acquired by prometic life sciences for